JPRN-jRCT1040220095招募中Unknown
A study to ascertain changes in blood urimic toxins in chronic kidney disease patients due to dietary treatment with sake lees: Open-label pilot randomized controlled trial - Sake lees CKD
Tokumaru Toshiaki0 个研究点目标入组 24 人开始时间: 2022年11月22日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients attending the outpatient department of nephrology at Kanazawa University Hospital
- •2) Patients whose most recent eGFR within 3 months prior to enrollment was between 15 mL/min/1.73 m2 and 59 mL/min/1.73 m2
- •3) Patients who meet the diagnostic criteria for chronic kidney disease
- •4) Patients whose age at the time of consent is 20 years or older
- •5) Patients whose performance status (ECOG) at the time of consent is 0
- •6) Patients who have given their free written consent to participate in this clinical trial after obtaining sufficient informed consent
排除标准
- •1) Patients on dialysis therapy
- •2) Patients after renal transplantation
- •3) Patients with cancer
- •4) Patients with Body Mass Index less than 16
- •5) Patients with primary and secondary immunodeficiency
- •6) Patients with inflammatory bowel disease
- •7) Patients with hepatic impairment or hepatic dysfunction
- •8) Patients who routinely take antibacterial drugs
- •9) Patients who routinely consume sake lees
- •10) Patients with alcohol intolerance
- •11) Patients with a history of antimicrobial use within the past 4 weeks from the time of study entry
- •12) Patients with a history of alcohol dependence
- •13) Patients who are deemed by the physician to be inappropriate to participate in this study
研究者
相似试验
已完成
不适用
Study of changes in blood and urine purine compounds by the administration of SG-1 (Compound A and B) or either of them.ormal adult malesJPRN-UMIN000022455Tsukuba International Clinical Pharmacology Clinic22
已完成
不适用
Changes of flow in Arterial anastomosis of Free flap after the Intraoperative administration of AlprostadilDiseases of the skin and subcutaneous tissueKCT0002166Asan Medical Center44
进行中（未招募）
不适用
Evaluation of the pharmacodynamic effect of the combination of Sildenafil and Riociguat on blood pressure and other safety parametersMedDRA version: 14.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersPulmonary arterial hypertensionEUCTR2010-018863-40-DEBayer HealthCare AG18
进行中（未招募）
不适用
An interaction study to evaluate changes in blood pressure following 1, 1.5, 2, and 2.5 mg riociguat tid (dose titration) compared to placebo treatment on the background of stable sildenafil pretreatment in subjects with symptomatic pulmonary arterial hypertension - PATENT PLUSPulmonary arterial hypertension.MedDRA version: 9.1Level: LLTClassification code 10064911EUCTR2010-018863-40-ITBayer Health Care AG36
进行中（未招募）
不适用
Evaluation of the pharmacodynamic effect of the combination of Sildenafil and Riociguat on blood pressure and other safety parametersPulmonary arterial hypertensionMedDRA version: 14.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-018863-40-CZBayer HealthCare AG36